WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotech company working to make daily pills a thing of the past, today announced the appointment of George Eldridge as Chief Financial Officer. As a seasoned industry veteran, Mr. Eldridge brings with him 27 years of experience leading biotechnology and life sciences companies in both the private and public sectors.
In this role, Mr. Eldridge will lead strategic global financial operations, including the management of potential financings, investor relations, mergers and acquisitions, and will build the Company’s presence on Wall Street.
“George’s tenure and extensive track record of success in high-level financial and corporate development positions make him an invaluable member of our expanding leadership team,” said Dr. Patricia Hurter, Chief Executive Officer of Lyndra Therapeutics. “The sophistication of our technology and our business requires top talent and industry expertise. We work hard to ensure our teams at all levels match the ambition and momentum of the Company and we look forward to working closely with George during this pivotal stage of growth.”
Mr. Eldridge has held Chief Financial Officer positions across a variety of life sciences companies, including most recently at Proteon Therapeutics, Inc., and prior to that at Targanta Therapeutics Corporation, Therion Biologics Corporation, and Curis, Inc. He has successfully taken four companies public, and throughout his career, he has fundraised extensively in a variety of environments, facilitated multiple successful mergers and acquisitions, and established, built and seamlessly integrated critical operations functions across businesses. Mr. Eldridge has also served as an independent consultant, providing senior financial and operational counsel to the leadership and Boards of several emerging life sciences companies. He holds a Bachelor’s degree from Dartmouth College and an MBA from The University of Chicago Booth School of Business.
“Lyndra Therapeutics is on track to drive a paradigm shift in the way patients and healthcare providers approach oral therapy, leveraging proprietary and innovative technology to address significant unmet medical needs,” stated Mr. Eldridge. “I’m thrilled to join this talented group of scientists and business professionals at this exciting time for the Company.”
Mr. Eldridge is the third senior management appointment in the last several months for Lyndra Therapeutics, following Dr. Örn Almarsson joining as the Company’s Chief Technology Officer in June and Dr. Richard Scranton as Chief Medical Officer in February. The Company is supporting aggressive manufacturing scale-up with hiring across the board, with an employee base that has grown more than 50% in 2020.
About Lyndra Therapeutics
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy and adherence to maximize global health impact and lower overall healthcare costs. For more information, visit the Company’s website www.lyndra.com.
